ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02954991

Public ClinicalTrials.gov record NCT02954991. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT02954991
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Mirati Therapeutics Inc.
Industry
Enrollment
161 participants

Conditions and interventions

Interventions

  • Glesatinib Drug
  • Mocetinostat Drug
  • Nivolumab Drug
  • Sitravatinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2016
Primary completion
Nov 3, 2021
Completion
Nov 3, 2021
Last update posted
Apr 21, 2024

2016 – 2021

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
Yuma Regional Medical Center Yuma Arizona 85364
Beverly Hills Cancer Center Beverly Hills California 90211
City of Hope National Medical Center Duarte California 91010
University of California San Diego La Jolla California 92093
University of California San Francisco Comprehensive Cancer Center San Francisco California 94115
University of California Los Angeles - Torrance - Community Cancer Care Santa Clarita California 91355
Rocky Mountain Cancer Centers - Denver - Midtown Denver Colorado 80218
Baptist Health Louisville Kentucky 40207
Henry Ford Hospital Detroit Michigan 48202
Minnesota Oncology Hematology, P.A. Minneapolis Minnesota 55404
University of Minnesota Masonic Cancer Center Minneapolis Minnesota 55455
Saint Francis Cancer Treatment Center Grand Island Nebraska 68803
Oncology Hematology Care-Blue Ash Cincinnati Ohio 45242
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Hematology Oncology Associates - Barnett Office Medford Oregon 97504
Northwest Cancer Specialists, P.C. Tualatin Oregon 97062
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Vanderbilt University Nashville Tennessee 37212
Texas Oncology - South Austin Austin Texas 78745
USOR - Texas Oncology - Denison Cancer Center Denison Texas 75020
MD Anderson Cancer Center Houston Texas 77030
Texas Oncology - Tyler Tyler Texas 75702
Virginia Cancer Specialist Fairfax Virginia 22031
University of Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02954991, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2024 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02954991 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →